vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Volato Group, Inc. (SOAR). Click either name above to swap in a different company.
Volato Group, Inc. is the larger business by last-quarter revenue ($24.9M vs $19.1M, roughly 1.3× NewAmsterdam Pharma Co N.V.). Volato Group, Inc. runs the higher net margin — 14.5% vs -90.7%, a 105.2% gap on every dollar of revenue. On growth, Volato Group, Inc. posted the faster year-over-year revenue change (13632.0% vs 740.1%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Volato Aeronaves also known as Volato Aeronaves e Compósitos Ltda is a Brazilian aircraft manufacturer.
NAMS vs SOAR — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $24.9M |
| Net Profit | $-17.4M | $3.6M |
| Gross Margin | — | 15.2% |
| Operating Margin | -186.1% | 3.5% |
| Net Margin | -90.7% | 14.5% |
| Revenue YoY | 740.1% | 13632.0% |
| Net Profit YoY | 55.5% | 121.3% |
| EPS (diluted) | $-0.15 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $19.1M | $24.9M | ||
| Q1 25 | — | $25.5M | ||
| Q4 24 | $12.8M | — | ||
| Q3 24 | $29.1M | $38.5M | ||
| Q4 23 | — | $3.2M | ||
| Q3 23 | — | $3.7M | ||
| Q2 23 | $8.6M | $13.0M | ||
| Q1 23 | — | $15.7M |
| Q2 25 | $-17.4M | $3.6M | ||
| Q1 25 | — | $455.0K | ||
| Q4 24 | $-92.2M | — | ||
| Q3 24 | $-16.6M | $-4.4M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-11.8M | ||
| Q2 23 | $-42.0M | $-9.9M | ||
| Q1 23 | — | $-7.5M |
| Q2 25 | — | 15.2% | ||
| Q1 25 | — | 17.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 16.6% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 8.7% | ||
| Q2 23 | — | -24.2% | ||
| Q1 23 | — | -10.8% |
| Q2 25 | -186.1% | 3.5% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | -338.5% | — | ||
| Q3 24 | -85.9% | 5.5% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -50.2% | ||
| Q2 23 | -461.8% | -71.3% | ||
| Q1 23 | — | -50.5% |
| Q2 25 | -90.7% | 14.5% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | -721.7% | — | ||
| Q3 24 | -57.2% | -11.5% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -323.6% | ||
| Q2 23 | -486.9% | -75.8% | ||
| Q1 23 | — | -48.0% |
| Q2 25 | $-0.15 | $0.75 | ||
| Q1 25 | — | $0.03 | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | $-0.18 | $-3.76 | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-0.71 | ||
| Q2 23 | $-0.51 | $-0.86 | ||
| Q1 23 | — | $-0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $-7.1M |
| Total Assets | $815.1M | $13.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $739.2M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $834.2M | — | ||
| Q3 24 | $422.7M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q2 25 | $778.5M | $-7.1M | ||
| Q1 25 | — | $-15.8M | ||
| Q4 24 | $757.5M | — | ||
| Q3 24 | $378.9M | $-19.6M | ||
| Q4 23 | — | $14.8M | ||
| Q3 23 | — | $-34.8M | ||
| Q2 23 | $398.4M | $-23.0M | ||
| Q1 23 | — | $-13.2M |
| Q2 25 | $815.1M | $13.0M | ||
| Q1 25 | — | $23.4M | ||
| Q4 24 | $864.6M | — | ||
| Q3 24 | $439.2M | $47.9M | ||
| Q4 23 | — | $71.7M | ||
| Q3 23 | — | $70.4M | ||
| Q2 23 | — | $70.9M | ||
| Q1 23 | — | $289.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $848.0K |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-37.7M | $848.0K | ||
| Q1 25 | — | $-312.0K | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.5M | $-3.1M | ||
| Q4 23 | — | $-30.4M | ||
| Q3 23 | — | $-10.9M | ||
| Q2 23 | $-31.9M | $-5.6M | ||
| Q1 23 | — | $-7.6M |
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | $-3.2M | ||
| Q4 23 | — | $-31.0M | ||
| Q3 23 | — | $-11.1M | ||
| Q2 23 | $-31.9M | $-5.9M | ||
| Q1 23 | — | $-7.9M |
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | -8.2% | ||
| Q4 23 | — | -958.0% | ||
| Q3 23 | — | -304.7% | ||
| Q2 23 | -369.3% | -45.6% | ||
| Q1 23 | — | -50.3% |
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q4 23 | — | 19.7% | ||
| Q3 23 | — | 7.4% | ||
| Q2 23 | 0.1% | 2.2% | ||
| Q1 23 | — | 1.7% |
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | -0.69× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
